SUTRO BIOPHARMA, INC.
STROSutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
STRO Earnings Report
EPS Est: $-2.09 | FQ end 2026-06
How STRO's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is SUTRO BIOPHARMA, INC.'s next FDA catalyst?→
SUTRO BIOPHARMA, INC.'s (STRO) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track STRO biotech catalysts?→
Add STRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SUTRO BIOPHARMA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.